Cargando…

Direct comparison of magnetic resonance imaging and pathological shrinkage patterns of triple-negative breast cancer after neoadjuvant chemotherapy

BACKGROUND: We aimed to investigate the usefulness of magnetic resonance imaging (MRI) and histopathological shrinkage patterns to formulate a predictive equation for estimating residual tumor size after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) patients. METHODS: We enr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshikawa, Katsuhiro, Ishida, Mitsuaki, Kan, Naoki, Yanai, Hirotsugu, Tsuta, Koji, Sekimoto, Mitsugu, Sugie, Tomoharu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374879/ https://www.ncbi.nlm.nih.gov/pubmed/32693794 http://dx.doi.org/10.1186/s12957-020-01959-9

Ejemplares similares

Presence of myxoid stromal change and fibrotic focus in pathological examination are prognostic factors of triple-negative breast cancer: Results from a retrospective single-center study
por: Yanai, Hirotsugu, et al.
Publicado: (2021)

Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2021)

Association between fatty acid synthase and adipophilin expression in triple-negative breast cancer
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2022)

Prognostic significance of adipophilin expression in biopsy specimens of patients with triple-negative breast cancer
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2022)

Adipophilin expression is an independent marker for poor prognosis of patients with triple-negative breast cancer: An immunohistochemical study
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2020)

Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2021)

Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2021)

Prognostic significance of the expression levels of T-cell immunoglobulin mucin-3 and its ligand galectin-9 for relapse-free survival in triple-negative breast cancer
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2022)

Immunohistochemical analyses of the expression profiles of INSM1, ATRX, DAXX and DLL3 in solid papillary carcinomas of the breast
por: Yanai, Hirotsugu, et al.
Publicado: (2022)

Intramural bronchogenic cysts of the esophagus and gastroesophageal junction: A case report
por: Matsuda, Hayato, et al.
Publicado: (2020)

Pathological Complete Response of Clinical T4b Ascending Colon Cancer after Preoperative Chemotherapy Using Pembrolizumab
por: Yoshida, Terufumi, et al.
Publicado: (2021)

Feasibility and Efficacy of Neoadjuvant Chemotherapy without Radiotherapy for Locally Advanced Rectal Cancer
por: Tokuhara, Katsuji, et al.
Publicado: (2022)

Pathological features of triple‐negative breast cancers that showed progressive disease during neoadjuvant chemotherapy
por: Tanabe, Yuko, et al.
Publicado: (2017)

Novel pathological predictive factors for extranodal extension in oral squamous cell carcinoma: a retrospective cohort study based on tumor budding, desmoplastic reaction, tumor-infiltrating lymphocytes, and depth of invasion
por: Noda, Yuri, et al.
Publicado: (2022)

Meta-Analysis of Shrinkage Mode After Neoadjuvant Chemotherapy for Breast Cancers: Association With Hormonal Receptor
por: Zheng, Chun-Hui, et al.
Publicado: (2022)

Multiparametric MRI radiomics fusion for predicting the response and shrinkage pattern to neoadjuvant chemotherapy in breast cancer
por: Fan, Ming, et al.
Publicado: (2023)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Nakashoji, Ayako, et al.
Publicado: (2017)

Temporary Tumor Shrinkage Following Enfortumab Vedotin Therapy for Metastatic Urothelial Carcinoma After Radical Cystectomy With Neoadjuvant Chemotherapy: A Case Report
por: Namiki, Sanae, et al.
Publicado: (2023)

Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple-negative breast cancer
por: Bao, Jean, et al.
Publicado: (2015)

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
por: Sivina, Elina, et al.
Publicado: (2023)

Wagner-Meissner neurilemmoma of the lip occurring in a patient with neurofibromatosis type 1: A case report
por: Miyasaka, Chika, et al.
Publicado: (2020)

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer
por: Chen, Victor E., et al.
Publicado: (2017)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response
por: Mohammed, Amrallah A, et al.
Publicado: (2020)

Pathologic method for extracting good prognosis group in triple‐negative breast cancer after neoadjuvant chemotherapy
por: Eguchi, Yuki, et al.
Publicado: (2022)

Usefulness and problems of cytological examination by endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of mediastinal lymphadenopathy: A retrospective single-centre study
por: Sandoh, Kaori, et al.
Publicado: (2021)

Significance of desmoplastic reactions on tumor deposits in patients with colorectal cancer
por: Kobayashi, Toshinori, et al.
Publicado: (2022)

Case report: administration of immune checkpoint inhibitor for SMARCB1 (INI1)-negative rhabdoid carcinoma with microsatellite instability (MSI)-high in the right colon
por: Kobayashi, Toshinori, et al.
Publicado: (2023)

Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy
por: Wu, Kunpeng, et al.
Publicado: (2014)

Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
por: Domergue, Camille, et al.
Publicado: (2022)

Use of neoadjuvant chemotherapy prior to radical hysterectomy in cervical cancer: monitoring tumour shrinkage and molecular profile on magnetic resonance and assessment of 3-year outcome
por: deSouza, N M, et al.
Publicado: (2004)

Tumor budding may be a promising prognostic indicator in intrahepatic cholangiocarcinoma: A multicenter retrospective study
por: Kosaka, Hisashi, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Immunohistochemical analysis of SOX2 expression in small-cell neuroendocrine carcinoma of the endometrium
por: Ebisu, Yusuke, et al.
Publicado: (2020)

A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes
por: Huang, Liang, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response
por: Weng, Zeng-Jie, et al.
Publicado: (2021)

Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers
por: Srivastava, Pooja, et al.
Publicado: (2022)

Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy
por: Toss, Angela, et al.
Publicado: (2022)

Prediction of Tumor Shrinkage Pattern to Neoadjuvant Chemotherapy Using a Multiparametric MRI-Based Machine Learning Model in Patients With Breast Cancer
por: Huang, Yuhong, et al.
Publicado: (2021)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_eovjn3puth7khfimdqt5dcgsd8